The challenges facing rollouts of coronavirus vaccines

The risks to vaccination programmes fall into three groups: procurement, deployment, and effectiveness. In the coming few months, deployment issues will be a key limiting factor in most countries. These should be overcome relatively quickly in DMs, but less so in EMs. Procurement problems will also be more acute in emerging economies, especially for those relying on COVAX. Further ahead, mutation and efficacy risks pose the biggest threats to rollouts. We’ll track the progress of rollouts on our coronavirus webpage.